Video Experimental Relacionado
Updated: Sep 10, 2025
11:48
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
Published on: April 4, 2019
16.1K
Estatus de las terapias antivirales para el virus sincitial respiratorio avanzado 2025
Claire E Ruckel1, Josef D Wolf1, Richard K Plemper1
1Center for Translational Antiviral Research, Georgia State University Institute for Biomedical Sciences, Atlanta, GA 30303, USA.
Current opinion in virology
|August 23, 2025
Resumen
El virus sincitial respiratorio (VSR) plantea riesgos significativos, especialmente para los bebés. Los tratamientos actuales son limitados, lo que requiere el desarrollo de nuevas terapias antivirales para combatir las enfermedades respiratorias graves.
Área de la Ciencia:
- Virología
- Inmunología
- Farmacología
Sus antecedentes:
- El virus sincitial respiratorio (VSR) es una causa importante de hospitalización infantil y enfermedades respiratorias graves.
- Las opciones de profilaxis existentes (vacunas, anticuerpos monoclonales) tienen limitaciones en cuanto a la accesibilidad y las poblaciones objetivo.
- El único antiviral aprobado, la ribavirina, ya no se recomienda, destacando una necesidad terapéutica no satisfecha.
Objetivo del estudio:
- Revisar los candidatos terapéuticos avanzados y los fármacos en investigación para el VSR.
- Evaluar el panorama actual del desarrollo de fármacos contra el VSR.
- Identificar los desafíos y los requisitos para el futuro manejo de la enfermedad por VSR.
Principales métodos:
- Centrarse en los candidatos terapéuticos avanzados y los fármacos en investigación en ensayos clínicos.
- Análisis de los avances recientes en la profilaxis del RSV.
- Evaluación de los esfuerzos de descubrimiento de fármacos dirigidos a la entrada viral, el complejo polimerasa y la nucleoproteína.
Principales resultados:
- El descubrimiento de fármacos se ha expandido más allá de los inhibidores de entrada viral para apuntar a otros componentes virales.
- Varios candidatos terapéuticos avanzados están progresando a través de ensayos clínicos.
- Los desafíos en el desarrollo de fármacos contra el VSR persisten a pesar de los avances recientes.
Conclusiones:
- Hay una necesidad urgente de terapias novedosas y efectivas para el VSR, especialmente para poblaciones vulnerables como los bebés.
- El futuro manejo de la enfermedad RSV requiere abordar las brechas terapéuticas actuales y optimizar las estrategias de desarrollo de fármacos.
- La investigación continua sobre diversos objetivos terapéuticos es crucial para combatir las infecciones por VSR.
Videos de Conceptos Relacionados
01:21Acute Respiratory Failure-II
360
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
360
01:21Acute Respiratory Failure-I
321
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
321
01:23Acute Respiratory Failure-IV
228
Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
228
01:16Drugs Used in Upper Respiratory Disorders: Overview
358
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
358
01:29Acute Respiratory Failure-V
205
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
205
01:30Acute Respiratory Failure-III
318
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
318